Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells

Immunobiology

Volumn 215, Issue 7, 2010, Pages 535-544

  Cantrell, Jessica ^a,b   Larmonier, Claire ^a   Janikashvili, Nona ^a   Bustamante, Sara ^a,b   Fraszczak, Jennifer ^c   Herrell, Amanda ^a   Lundeen, Tamara ^a   J LaCasse, Collin ^a   Situ, Elaine ^a   Larmonier, Nicolas ^a,b,d   Katsanis, Emmanuel ^a,b,d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Institut Médical de Génétique et d Immunologie   (France)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cell signaling; Dendritic cells; Macrophages; Tumor vaccines

Indexed keywords

CD70 ANTIGEN; CHAPERONE RICH CELL LYSATE VACCINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STAT1 PROTEIN; STAT5 PROTEIN; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; CELL EXTRACT; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE ACTIVATION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEUKEMIA; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; ANIMAL; ANTIGEN PRESENTATION; CYTOTOXICITY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL EXTRACTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77953538002     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.09.006     Document Type: Article

References (50)

1. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
2. Asea A., Kraeft S.K., Kurt-Jones E.A., Stevenson M.A., Chen L.B., Finberg R.W., Koo G.C., Calderwood S.K. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 2000, 6:435-442.
3. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
4. Bauer P.M., Buga G.M., Fukuto J.M., Pegg A.E., Ignarro L.J. Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J. Biol. Chem. 2001, 276:34458-34464.
5. Binder R.J., Han D.K., Srivastava P.K. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 2000, 1:151-155.
6. Binder R.J., Vatner R., Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004, 64:442-451.
7. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907-916.
8. Bonnotte B., Larmonier N., Favre N., Fromentin A., Moutet M., Martin M., Gurbuxani S., Solary E., Chauffert B., Martin F. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J. Immunol. 2001, 167:5077-5083.
9. Cheng F., Wang H.W., Cuenca A., Huang M., Ghansah T., Brayer J., Kerr W.G., Takeda K., Akira S., Schoenberger S.P., Yu H., Jove R., Sotomayor E.M. A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19:425-436.
10. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
11. Gao B., Tsan M.F. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J. Biol. Chem. 2003, 278:174-179.
12. Graner M., Raymond A., Akporiaye E., Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 2000, 49:476-484.
13. Graner M., Raymond A., Romney D., He L., Whitesell L., Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin. Cancer Res. 2000, 6:909-915.
14. Graner M.W., Likhacheva A., Davis J., Raymond A., Brandenberger J., Romanoski A., Thompson S., Akporiaye E., Katsanis E. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res. 2004, 64:8085-8092.
15. Graner M.W., Zeng Y., Feng H., Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 2003, 52:226-234.
16. He L., Feng H., Raymond A., Kreeger M., Zeng Y., Graner M., Whitesell L., Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother. 2001, 50:31-40.
17. Heike M., Weinmann A., Bethke K., Galle P.R. Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines. Biochem. Pharmacol. 1999, 58:1381-1387.
18. Hennighausen L., Robinson G.W. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 2008, 22:711-721.
19. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
20. Kawai, T., Akira, S., 2006. TLR signaling. Cell Death Differ.
21. Klimp A.H., de Vries E.G., Scherphof G.L., Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002, 44:143-161.
22. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., Lackner A., Alvarez X., Ochoa A., Chen L., Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203:871-881.
23. Larmonier N., Cantrell J., Lacasse C., Li G., Janikashvili N., Situ E., Sepassi M., Andreansky S., Katsanis E. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J. Leukoc. Biol. 2008, 83:1049-1059.
24. Larmonier N., Janikashvili N., LaCasse C.J., Larmonier C.B., Cantrell J., Situ E., Lundeen T., Bonnotte B., Katsanis E. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J. Immunol. 2008, 181:6955-6963.
25. Larmonier N., Marron M., Zeng Y., Cantrell J., Romanoski A., Sepassi M., Thompson S., Chen X., Andreansky S., Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. 2007, 56:48-59.
26. Larmonier N., Merino D., Nicolas A., Cathelin D., Besson A., Bateman A., Solary E., Martin F., Katsanis E., Bonnotte B. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 2006, 11:1513-1524.
27. Li Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin. Immunol. 1997, 9:315-322.
28. Li Z., Menoret A., Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr. Opin. Immunol. 2002, 14:45-51.
29. McLaughlin J., Chianese E., Witte O.N. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 1987, 84:6558-6562.
30. Nathan C. Nitric oxide as a secretory product of mammalian cells. Faseb J. 1992, 6:3051-3064.
31. Nicchitta C.V. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat. Rev. Immunol. 2003, 3:427-432.
32. Pervin S., Singh R., Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc. Natl. Acad. Sci. USA 2001, 98:3583-3588.
33. Radsak M.P., Hilf N., Singh-Jasuja H., Braedel S., Brossart P., Rammensee H.G., Schild H. The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood 2003, 101:2810-2815.
34. Reed R.C., Berwin B., Baker J.P., Nicchitta C.V. GRP94/gp96 elicits ERK activation in murine macrophages. A role for endotoxin contamination in NF-kappa B activation and nitric oxide production. J. Biol. Chem. 2003, 278:31853-31860.
35. Sanchez P.J., McWilliams J.A., Haluszczak C., Yagita H., Kedl R.M. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 2007, 178:1564-1572.
36. Segal B.H., Wang X.Y., Dennis C.G., Youn R., Repasky E.A., Manjili M.H., Subjeck J.R. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov. Today 2006, 11:534-540.
37. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3:900-911.
38. Smith D.F., Whitesell L., Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 1998, 50:493-514.
39. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 2002, 20:395-425.
40. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2002, 2:185-194.
41. Srivastava P.K., Amato R.J. Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine 2001, 19:2590-2597.
42. Srivastava P.K., Menoret A., Basu S., Binder R.J., McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998, 8:657-665.
43. Srivastava P.K., Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 1994, 6:728-732.
44. Tesselaar K., Xiao Y., Arens R., van Schijndel G.M., Schuurhuis D.H., Mebius R.E., Borst J., van Lier R.A. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 2003, 170:33-40.
45. Wallin R.P., Lundqvist A., More S.H., von Bonin A., Kiessling R., Ljunggren H.G. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 2002, 23:130-135.
46. Wells A.D., Malkovsky M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol. Today 2000, 21:129-132.
47. Xie K., Dong Z., Fidler I.J. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J. Leukoc Biol. 1996, 59:797-803.
48. Zeng Y., Feng H., Graner M.W., Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003, 101:4485-4491.
49. Zeng Y., Graner M.W., Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol. Immunother. 2006, 55:329-338.
50. Zeng Y., Graner M.W., Thompson S., Marron M., Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood 2005, 105:2016-2022.